Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …

Introduction Ruxolitinib has been the cornerstone of pharmacologic therapy for myelofibrosis
for over a decade. However, the last several years have witnessed the regulatory approval …

In patients with cytopenic myelofibrosis, treatment with the JAK2/IRAK1 inhibitor pacritinib
was associated with anemia benefit in the phase 3 PERSIST-2 study. The impact of …

Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by
systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors …

Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET)
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …

Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of
allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor …

Inflammation and bone marrow fibrosis: novel immunotherapeut... : Current Opinion in
Hematology Inflammation and bone marrow fibrosis: novel immunotherapeutic targets …

Primary myelofibrosis (PMF) patients frequently have JAK2 (V617F), CALR (exon 9), or MPL
(W515 or exon 10) strong driver gene mutation, which triggers abnormal activation of the …

Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-
like receptor-mediated signaling pathways. They play essential roles in innate immunity and …

Abstract Development of myelofibrosis (MF) therapeutics has reached fruition as the
transformative impact of JAK2 inhibitors in the MPN landscape is complemented/expanded …